Literature DB >> 10663630

Actinomycin D and staurosporine, potent apoptosis inducers in vitro, are potentially effective chemotherapeutic agents against glioblastoma multiforme.

Y Narita1, A Asai, Y Kuchino, T Kirino.   

Abstract

PURPOSE: Although chemotherapeutic protocols that include chloroethylnitrosoureas (CENUs), such as 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) and 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU), have been a mainstay of treatment for glioblastomas, the clinical outcomes have been unsatisfactory. More effective chemotherapeutic protocols for these tumors will require clear delineation of more cytocidal and cytostatic chemotherapeutic drugs. METHODS AND
RESULTS: In this study, we measured the cytocidal effects of ACNU, cisplatin, actinomycin D, and staurosporine, administered within their therapeutic dose ranges, in the treatment of glioblastoma cells. As assessed by WST-1 colorimetric assay, the number of viable cells decreased markedly in T98G cultures treated with actinomycin D or staurosporine, to less than 20% of the level in control cultures at 72 h, but did not decrease or even increased after 6 days of treatment with ACNU. After treatment with cisplatin for 5 days, cell viability decreased to 30% of control. As assessed by fluorescence microscopic examination of nuclear staining by Hoechst 33258 and by electron microscopy, the majority of dead cells treated with actinomycin D, staurosporine, or cisplatin had morphologic features of apoptosis. Caspase-3 activity increased more than 20-fold in cells treated with actinomycin D, staurosporine, or cisplatin but increased less than fivefold in ACNU-treated cells. In addition to caspase-3 activation, western blot analysis demonstrated cleavage of caspase-2 during the apoptotic process. These findings indicate that actinomycin D and staurosporine potently induce apoptosis, whereas ACNU exerts mainly a cytostatic rather than a cytocidal effect.
CONCLUSION: Actinomycin D and staurosporine and their derivatives are potentially effective chemotherapeutic agents against glioblastoma cells at least in vitro.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10663630     DOI: 10.1007/s002800050023

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  5 in total

1.  Effect of staurosporine on cycle of human gastric cancer cells.

Authors:  Min-Wen Ha; Ke-Zuo Hou; Yun-Peng Liu; Yuan Yuan
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

2.  Inhibition of neurotensin receptor 1 induces intrinsic apoptosis via let-7a-3p/Bcl-w axis in glioblastoma.

Authors:  Zhen Dong; Qian Lei; Rui Yang; Shunqin Zhu; Xiao-Xue Ke; Liqun Yang; Hongjuan Cui; Liang Yi
Journal:  Br J Cancer       Date:  2017-05-11       Impact factor: 7.640

3.  Methylene blue photodynamic therapy induces selective and massive cell death in human breast cancer cells.

Authors:  Ancély F Dos Santos; Letícia F Terra; Rosangela A M Wailemann; Talita C Oliveira; Vinícius de Morais Gomes; Marcela Franco Mineiro; Flávia Carla Meotti; Alexandre Bruni-Cardoso; Maurício S Baptista; Leticia Labriola
Journal:  BMC Cancer       Date:  2017-03-15       Impact factor: 4.430

4.  High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma.

Authors:  Kenny Kwok-Hei Yu; Jessica T Taylor; Omar N Pathmanaban; Amir Saam Youshani; Deniz Beyit; Joanna Dutko-Gwozdz; Roderick Benson; Gareth Griffiths; Ian Peers; Peter Cueppens; Brian A Telfer; Kaye J Williams; Catherine McBain; Ian D Kamaly-Asl; Brian W Bigger
Journal:  PLoS One       Date:  2018-03-02       Impact factor: 3.240

5.  Neutral metalloaminopeptidases APN and MetAP2 as newly discovered anticancer molecular targets of actinomycin D and its simple analogs.

Authors:  Ewelina Węglarz-Tomczak; Michał Talma; Mirosław Giurg; Hans V Westerhoff; Robert Janowski; Artur Mucha
Journal:  Oncotarget       Date:  2018-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.